Burning Rock Biotech (BNR) Stock Price, News & Analysis

Company Overview

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Key Stats

• Today's Range: $2.80 to $2.94
• 50-Day Range: $2.90 to $7.90
• 52-Week Range: $2.62 to $8.99
• Volume: 11,668 shs
• Average Volume: 15,022 shs
• Market Capitalization: $28.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Burning Rock Biotech Stock Analysis - MarketRank™

Burning Rock Biotech scored higher than 21% of companies evaluated by MarketBeat, and ranked 277th out of 321 stocks in the business services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Burning Rock Biotech.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Burning Rock Biotech is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Burning Rock Biotech is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Burning Rock Biotech has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.56% of the float of Burning Rock Biotech has been sold short.

Short Interest Ratio / Days to Cover

Burning Rock Biotech has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Burning Rock Biotech has recently decreased by 2.14%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Burning Rock Biotech does not currently pay a dividend.

Dividend Growth

Burning Rock Biotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.56% of the float of Burning Rock Biotech has been sold short.

Short Interest Ratio / Days to Cover

Burning Rock Biotech has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Burning Rock Biotech has recently decreased by 2.14%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Burning Rock Biotech has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Business Services companies.

Search Interest

1 people have searched for BNR on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Burning Rock Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.30% of the stock of Burning Rock Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 30.03% of the stock of Burning Rock Biotech is held by institutions.

BNR Stock Analysis - Frequently Asked Questions

How have BNR shares performed this year?

Burning Rock Biotech's stock was trading at $6.75 on January 1st, 2025. Since then, BNR stock has decreased by 58.1% and is now trading at $2.8250.
View the best growth stocks for 2025 here.

How were Burning Rock Biotech's earnings last quarter?

Burning Rock Biotech Limited (NASDAQ:BNR) posted its quarterly earnings data on Tuesday, March, 25th. The company reported ($1.08) earnings per share for the quarter, topping the consensus estimate of ($1.40) by $0.32. The firm had revenue of $17.27 million for the quarter. Burning Rock Biotech had a negative trailing twelve-month return on equity of 60.68% and a negative net margin of 83.50%.

When did Burning Rock Biotech's stock split?

Burning Rock Biotech shares reverse split on Wednesday, May 15th 2024. The 1-10 reverse split was announced on Wednesday, May 15th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Burning Rock Biotech IPO?

Burning Rock Biotech (BNR) raised $196 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 13,500,000 shares at a price of $13.50-$15.50 per share. Morgan Stanley, BofA Securities and Cowen served as the underwriters for the IPO and CMBI and Tiger Brokers were co-managers.

How do I buy shares of Burning Rock Biotech?

Shares of BNR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Burning Rock Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Burning Rock Biotech investors own include Tesla (TSLA), NVIDIA (NVDA), Intel (INTC), Vertex Pharmaceuticals (VRTX), HubSpot (HUBS), NIO (NIO) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 3/25/2025
• Today: 4/17/2025
• Next Earnings (Estimated): 6/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Business Services
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:BNR
• CIK: 1792267
• Web: www.brbiotech.com
• Phone: 86-185-0164-1666
• Fax: N/A
• Employees: 1,390
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-92,070,000.00
• Net Margins: -83.50%
• Pretax Margin: -83.40%
• Return on Equity: -60.68%
• Return on Assets: -42.30%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.04
• Quick Ratio: 2.78

Sales & Book Value

• Annual Sales: $515.82 million
• Price / Sales: 0.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.56 per share
• Price / Book: 0.27

Miscellaneous

• Outstanding Shares: 10,244,000
• Free Float: 7,140,000
• Market Cap: $29.71 million
• Optionable: Not Optionable
• Beta: 0.67